411 related articles for article (PubMed ID: 25728680)
21. c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination.
Taher TE; Tjin EP; Beuling EA; Borst J; Spaargaren M; Pals ST
J Immunol; 2002 Oct; 169(7):3793-800. PubMed ID: 12244174
[TBL] [Abstract][Full Text] [Related]
22. Keratin 19 Expression in Hepatocellular Carcinoma Is Regulated by Fibroblast-Derived HGF via a MET-ERK1/2-AP1 and SP1 Axis.
Rhee H; Kim HY; Choi JH; Woo HG; Yoo JE; Nahm JH; Choi JS; Park YN
Cancer Res; 2018 Apr; 78(7):1619-1631. PubMed ID: 29363547
[TBL] [Abstract][Full Text] [Related]
23. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization.
Wu YM; Liu CH; Huang MJ; Lai HS; Lee PH; Hu RH; Huang MC
Cancer Res; 2013 Sep; 73(17):5580-90. PubMed ID: 23832667
[TBL] [Abstract][Full Text] [Related]
24. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway.
Tan S; Li R; Ding K; Lobie PE; Zhu T
FEBS Lett; 2011 Jul; 585(14):2229-34. PubMed ID: 21658389
[TBL] [Abstract][Full Text] [Related]
25. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
26. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.
Bozkaya G; Korhan P; Cokaklı M; Erdal E; Sağol O; Karademir S; Korch C; Atabey N
Mol Cancer; 2012 Sep; 11():64. PubMed ID: 22962849
[TBL] [Abstract][Full Text] [Related]
27. Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53.
Liu WT; Jing YY; Yu GF; Chen H; Han ZP; Yu DD; Fan QM; Ye F; Li R; Gao L; Zhao QD; Wu MC; Wei LX
Cell Cycle; 2016; 15(7):886-94. PubMed ID: 27077227
[TBL] [Abstract][Full Text] [Related]
28. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
29. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling.
Yu J; Xia X; Dong Y; Gong Z; Li G; Chen GG; Lai PBS
Theranostics; 2021; 11(5):2123-2136. PubMed ID: 33500715
[No Abstract] [Full Text] [Related]
30. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
[TBL] [Abstract][Full Text] [Related]
31. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
Calvisi DF; Ladu S; Gorden A; Farina M; Conner EA; Lee JS; Factor VM; Thorgeirsson SS
Gastroenterology; 2006 Apr; 130(4):1117-28. PubMed ID: 16618406
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylation of cMet tyrosine residues in murine ascitic hepatic cancer cell lines with different lymph node metastatic potentials.
Li Y; Huang X; Zhang Q; Ma K
Mol Med Rep; 2013 Aug; 8(2):655-61. PubMed ID: 23778885
[TBL] [Abstract][Full Text] [Related]
33. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.
García-Vilas JA; Medina MÁ
World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476
[TBL] [Abstract][Full Text] [Related]
34. Targeting Lyn tyrosine kinase through protein fusions encompassing motifs of Cbp (Csk-binding protein) and the SOCS box of SOCS1.
Whiting RJ; Payne CJ; Satiaputra J; Kucera N; Qiu TW; Irtegun S; Gunn NJ; Slavova-Azmanova NS; Mulhern TD; Ingley E
Biochem J; 2012 Mar; 442(3):611-20. PubMed ID: 22364282
[TBL] [Abstract][Full Text] [Related]
35. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.
Jo JC; Choi EK; Shin JS; Moon JH; Hong SW; Lee HR; Kim SM; Jung SA; Lee DH; Jung SH; Lee SH; Kim JE; Kim KP; Hong YS; Suh YA; Jang SJ; Choi EK; Lee JS; Jin DH; Kim TW
Mol Cancer Ther; 2015 Nov; 14(11):2613-22. PubMed ID: 26351320
[TBL] [Abstract][Full Text] [Related]
36. Anti-neoplastic Effect of Ginkgolide C through Modulating c-Met Phosphorylation in Hepatocellular Carcinoma Cells.
Yang MH; Baek SH; Um JY; Ahn KS
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167504
[TBL] [Abstract][Full Text] [Related]
37. Hypermethylation of suppressor of cytokine signaling 1 in hepatocellular carcinoma patients.
Saelee P; Chuensumran U; Wongkham S; Chariyalertsak S; Tiwawech D; Petmitr S
Asian Pac J Cancer Prev; 2012; 13(7):3489-93. PubMed ID: 22994783
[TBL] [Abstract][Full Text] [Related]
38. Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion.
Kaufmann R; Oettel C; Horn A; Halbhuber KJ; Eitner A; Krieg R; Katenkamp K; Henklein P; Westermann M; Böhmer FD; Ramachandran R; Saifeddine M; Hollenberg MD; Settmacher U
Carcinogenesis; 2009 Sep; 30(9):1487-96. PubMed ID: 19546160
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of hematological and neurological expressed 1 (HN1) is associated with a poor prognosis of hepatocellular carcinoma and its knockdown inhibits cell growth and migration partly by down-regulation of c-Met.
Chen JJ; Sun X; Mao QQ; Jiang XY; Zhao XG; Xu WJ; Zhong L
Kaohsiung J Med Sci; 2020 Mar; 36(3):196-205. PubMed ID: 31749294
[TBL] [Abstract][Full Text] [Related]
40. Trabid inhibits hepatocellular carcinoma growth and metastasis by cleaving RNF8-induced K63 ubiquitination of Twist1.
Zhu Y; Qu C; Hong X; Jia Y; Lin M; Luo Y; Lin F; Xie X; Xie X; Huang J; Wu Q; Qiu X; Piao D; Xing Y; Yu T; Lu Y; Huang Q; Yu C; Jin J; Zhang Z
Cell Death Differ; 2019 Jan; 26(2):306-320. PubMed ID: 29748601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
